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Aspermatogenesis is a severe impairment of spermatogenesis in which germ cells are completely lacking or
present in an immature form, which results in sterility in approximately 25% of patients. Because assisted
reproduction techniques require mature germ cells, biotechnology is a valuable tool for rescuing fertility while
maintaining biological fatherhood. However, this process involves, for instance, the differentiation of
preexisting immature germ cells or the production/derivation of sperm from somatic cells. This review critically
addresses four potential techniques: sperm derivation in vitro, germ stem cell transplantation, xenologous
systems, and haploidization. Sperm derivation in vitro is already feasible in fish and mammals through organ
culture or 3D systems, and it is very useful in conditions of germ cell arrest or in type II Sertoli-cell-only
syndrome. Patients afflicted by type I Sertoli-cell-only syndrome could also benefit from gamete derivation
from induced pluripotent stem cells of somatic origin, and human haploid-like cells have already been obtained
by using this novel methodology. In the absence of alternative strategies to generate sperm in vitro, in germ
cells transplantation fertility is restored by placing donor cells in the recipient germ-cell-free seminiferous
epithelium, which has proven effective in conditions of spermatogonial arrest. Grafting also provides an
approach for ex-vivo generation of mature sperm, particularly using prepubertal testis tissue. Although less
feasible, haploidization is an option for creating gametes based on biological cloning technology. In
conclusion, the aforementioned promising techniques remain largely experimental and still require extensive
research, which should address, among other concerns, ethical and biosafety issues, such as gamete epigenetic
status, ploidy, and chromatin integrity.
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& INTRODUCTION
Beyond the apparent anatomical simplicity of the male
reproductive system, which has a basic design consisting of a
pair of gonads with its corresponding excurrent ducts and
associated accessory sexual glands, there lies an overwhel-
mingly complex system that is responsible for gamete
production and transport into the female tract for ultimate
sexual reproduction. Although many aspects of the endo-
crine regulation of testis function are well understood and
therapeutic options for hypogonadal men are available,
many aspects of the multiple physiological processes
involved in gamete development inside the testis are often
deregulated and out of homeostasis, with the subsequent
outcome of absent or disturbed spermatogenesis, which leads
to infertility. Human infertility is usually defined as the
inability of couples to achieve pregnancy after 12 months of
unprotected intercourse and is a problem that currently
affects 10 to 15% of couples. An outstanding 50% of these
cases are associated with male factors (1,2)
Specific etiologies of male infertility include systemic
diseases (e.g., endocrine, infectious, and cancer), varicoceles,
obstructive syndromes, genetic/chromosomal factors, testi-
cular failure/hypogonadism, and cryptorchidism. Of all of
the causes reported, approximately 12% of the determinants
of primary dysfunction in the male reproductive organs are
of unknown origin and are usually confounded by the
context of multicausal origins (Figure 1).
Furthermore, it is clear that many cases of infertility are
secondary to general systemic diseases or congenital
defects, with reproductive consequences that may be treated
when appropriate state-of-the-art procedures are implemen-
ted. Data in the literature show that 25 to 75% of cases
(depending on the report/study) could theoretically be
treated medically and/or surgically (Figure 1). In many
cases, very few sperm are present in the testes, and they can
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be retrieved by biopsy and testicular sperm extraction from
the tissue. Patients with access to assisted reproductive
technologies (ART) can undergo ICSI (intracytoplasmatic
sperm injection), which is routinely used in many fertility
centers worldwide, to achieve pregnancy. However, the
group of patients for whom ART procedures are not an
option deserves special attention. These men present with
azoospermia and varying degrees of germ cell pathology,
from germinal aplasia to germ cell premeoitic/meiotic
arrest. This group of testicular pathologies has a poor
prognosis and holds the status of being untreatable and
incurable from a medical point of view. We propose that
men with incomplete spermatogenesis could be collectively
classified as aspermatogenic, i.e., having a severe testicular
pathology with a complete absence of spermatids. Such men
comprise from 25 to 50% of andrological cases (3,4) (see
Figure 1), and the only option currently available for these
patients is adoption or artificial insemination using donor
sperm.
Histopathologic findings in biopsies from patients in the
aspermatogenic group can be classified as: a) Sertoli cell
only (SCO) syndrome, which strictly consists of testes
presenting a complete absence of germ cells; b) arrest at
the level of meiotic germ cells; or c) spermatogonia only
(pre-meiotic arrest) (Figure 2).
Sertoli cell only syndrome, i.e., type I SCO, refers to a
situation in which testicular biopsy reveals an absence of
germ cells in the seminiferous tubules (5). The presence of
few seminiferous tubules showing active spermatogenesis
has also been referred as to focal SCO (6) or type II SCO
(MeSH database PubMed). However, in contrast to patients
with complete SCO, these patients benefit from ART
procedures, as their sperm can be retrieved by TESE
(testicular sperm extraction). Type I SCO can have a
genetically determined developmental origin that results in
the disturbance of migration and/or colonization of primor-
dial germ cells (PGCs) into the genital ridges. Because the
diagnosis of type I or type II SCO depends on histopathologic
analysis, which is of course prone to sampling error (because
biopsies cover only a very small portion of the testis), the
subtypes of SCO are often misdiagnosed. The situation
would present less of a diagnostic challenge if a reliable, non-
invasive method were available to distinguish cases of partial
and complete absence of germ cells. The first steps in this
direction involved the amplification of specific germ cells,
seminal vesicles and prostate mRNA from cell-free seminal
mRNA by using RT-PCR (7). Combinations of non-invasive
diagnostic procedures with other procedures, such as
hormonal profiles and histopathology, may unequivocally
help to diagnose patients correctly. As type I SCO patients
have no germ cells, the only possible way to generate
offspring would be the use of their somatic cells to generate
germline cells in vitro.
Arrest represents a situation in which spermatogenesis
stops at a specific stage of germ cell development.
McLachlan et al. proposed a nomenclature in which the
term arrest exclusively refers to histological samples in
which no progression occurs beyond that specific stage in
any seminiferous tubule (5). Arrest can represent an
intermediate step on the way to more severe germ cell
Figure 1 - Frequency of male infertility etiological groups determined from reproductive clinic records. Percentages for each category
are presented as ranges (minimum and maximum values in the reported literature) (3,4). Patients from Group A (27.8 to 73.8% of cases)
can undergo medical or surgical treatments to address their infertility problems. An unknown percentage of cases within Group B
(idiopathic azoospermia) and perhaps even some from Group C can benefit from ART, provided that their sperm can be retrieved. Men
suffering from aspermatogenesis, with some type of premeiotic/meiotic spermatogenic disturbance, are included in Group C.
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losses. Arrest occurs often at the spermatocytes or sperma-
togonial level (12.5% and 1.7% of 534 patients, respectively)
(5). Arrest during spermiogenesis is rare, and hyposperma-
togenesis (often misdiagnosed as arrest), in which a lower
spermatid count is combined with the presence of all
spermatogenic stages, which are reduced to some extent,
accounts for up to 63% of cases (7). In any case, because
hypospermatogenesis results in the presence of spermatids,
ART procedures are applicable. Given that germ cells are
present in cases of arrest, an interesting strategy would be to
differentiate these cells in vitro to obtain sperm for ICSI or
IVF (in vitro fertilization). Interestingly, in arrest at the level
of meiotic cells, these cells can be injected into oocytes to
produce viable embryos and even offspring (8-10).
Nevertheless, intracytoplasmatic spermatocyte injection is
only an experimental optionwith low efficiency. For instance,
only 15% of mouse oocytes injected with secondary sperma-
tocytes generated offspring, whereas those injected with
primary spermatocytes generated none (8). Furthermore, in
another set of experiments, from 0 to 9% of eggs ‘‘fertilized’’
by primary spermatocytes developed into adult fertile mice
(9). In humans, one report showed an offspring-deriving
efficiency of approximately 3% (10). For these reasons, the
use of spermatocytes to compensate for a lack of moremature
male germ cells will require further experimentation.
Many patients believe that biological fatherhood has a
very high value. In this respect, biotechnology offers, now
more than ever, a basis on which to develop clinical
applications for such cases, to restore fertility and conse-
quently to obtain offspring. In this context, advances in cell
biology from several animal models are waiting to be
translated into human reproductive medicine, provided that
some technical issues and biosafety and ethical concerns are
overcome.We propose fourmain groups of technologies that,
alone or combined, could bring hope to men with severe
cases of aspermatogenesis: i) sperm derivation in vitro; ii)
germ stem cell transplantation; iii) xenologous systems; and
iv) haploidization. These topics are addressed below.
& SPERM DERIVATION IN VITRO
The complex spatial and functional organization of the
testis and its seminiferous epithelium make it difficult to
achieve efficient spermatogenesis in artificial systems. The
observation of at least a few aspects of spermatogenesis in
culture dishes has been a scientific aim for decades (17,18).
Spermatogenesis in vitro is not only a long-desired
technique to gain deeper insight into the complex process
of gametogenesis; it is also desired for clinical applications
to broaden the therapeutic options for men with infertility
problems. Given the current status of ART and the
requirement of only one sperm to fertilize an oocyte through
ICSI, the in vivo physiological situation, in which millions of
sperm (many more than needed) are produced on a daily
basis may be surpassed by in vitro strategies, which may be
inefficient but which can generate a few fully mature sperm
for ART procedures.
Spermatogenesis in vitro was first successfully achieved
in vertebrates by using a fish model that consisted of a tissue
culture system that supported full spermatogenesis in
Japanese eels (19,20), which opened the possibility for
Figure 2 - Schematic summary of the types of seminiferous epithelium impairment that can lead to infertility in men. Group I
summarizes pathologies in which germ cell arrest occurs at spermiogenesis. (a) Presents an apparently normal seminiferous tubule with
apparently normal sperm and elongated spermatids as the most advanced cell types present. Several pathologies show a
morphologically normal seminiferous epithelium, as depicted, but sperm can still present a pathological condition and therefore be
unable to fertilize an egg. Many of these cases can be solved by using ART, i.e., testicular sperm extraction (TESE) combined with ICSI.
(b) Arrest at the level of round spermatids, which can be used for ROSI (round spermatid injection). This type of arrest is rare. Group II
represents arrest at the levels of (c) spermatocytes (12.5 % of cases) or (d) spermatogonial cells (1.7 % of cases) and (e) total absence of
germ cells, as in SCO syndrome (estimated to occur in 16.5 % of cases, based on data from Tuttelmann (2010) (3), with detailed
etiological entities including chromosomal aberrations, as in Klinefelter (11), XX males (12), translocations (13,14) and microdeletions
at the level of the AZF regions of the Y chromosome (15,16). Prevalence data are from McLachlan et al. (2007) (5), except for the SCO
data (3).
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similar technological advances in higher vertebrates.
Systems for in vitro spermatogenesis in fish seem to be
very simple from a practical point of view. For example, one
such system based on a spermatogonial cell line without
Sertoli cells and involving medaka fish, allowed postmeiotic
advances in the presence of a culture medium containing a
crude embryo extract with no specific growth factors added
(21), which introduced the idea that germ cells in lower
vertebrates are more intrinsically programmed and less
dependent on regulation by extrinsic signals.
Currently, two main experimental approaches dominate
the efforts to generate mammalian sperm in culture systems:
organ culture of testes or testicular fragments that maintain
the complex architecture of testicular tissue and its
arrangement inside the epithelium. A recent article by
Sato et al. convincingly demonstrated, in what has been
described as a great scientific breakthrough, the feasibility of
obtaining viable and apparently normal offspring from
sperm generated through testicular tissue explants that
initially contained immature germ cells (22). In this
approach, the cytoarchitecture of the gonad remains widely
preserved in the system, many endogenous factors are
produced and released by the mostly intact seminiferous
epithelium, and associated somatic cells regulate the germ
cells in the system similarly to the in vivo condition. In
dissected tissue, the supply of oxygen and nutrients is
disturbed, and therefore the spermatogenic process is often
disrupted and continues, at best, at low efficiency (22).
Alternatively, enzymatically digested cell suspensions can
be used for various culture systems. The supply of oxygen
and nutrients to isolated cells is achieved by modern cell
culture media under appropriate culture conditions.
However, the seminiferous tubule microenvironment, with
its different, functionally distinct compartments (e.g., inter-
stitial, basal, intraepithelial, and adluminal), is destroyed. If
these changes in the microenvironment during germ cell
differentiation are significant, then spermatogenesis will be
disrupted. Although many additional strategies of cell and
tissue culture have been tested over the last 30 years, success
has been limited (23-29). Recent studies have used mono-
layers other than those generated from Sertoli cells as
sources of differentiating factors (30-33). Because the
production of sperm in higher vertebrates involves an
overwhelmingly intricate process of germ cell differentia-
tion, further research efforts have been directed toward
identifying signaling pathways associated with differentia-
tion in the seminiferous epithelium during spermatogenesis.
To incorporate this knowledge into the development of in
vitro spermatogenesis systems, studies that have addressed
the presence of substances such as retinol (34,35), kit ligand
(stem cell factor) (36,37), insulin-like growth factor and
transforming growth factor alpha (TGF-alpha) (38), as well
as hormones such as testosterone (39) and FSH (40), among
others, have been instrumental in recapitulating the entire
differentiation process. These studies will become particu-
larly valuable if the paradigm of spermatogenesis in vitro,
as a model of the in vivo situation, is accepted. Therefore,
other factors, such as scrotal temperature, the timing of
cellular events and the presence of important culture media
components, e.g., fetal calf serum, oxygen levels, pressure,
substrates and the use of feeder layers, should be carefully
evaluated and whenever possible translated from the in
vivo situation to the artificial system. The use of Sertoli cells
is controversial but, in principle, these cells are important
for the maintenance of germ cells in culture and to provide
differentiating factors (41-44). Among the advantages of cell
culture systems is that such systems (cell cultures started
from dissociated germ cell suspensions) are much simpler
than tissue cultures, in which cell function is tightly
regulated and more complex, as in the in vivo situation.
Cell cultures can be started with purified, selected, isolated
cells, thereby allowing uncomplicated manipulation
schemes because signal redundancy, which is observed in
intact biological systems, is minimized. Furthermore, as the
first step of the procedure, germ cells can be stimulated to
proliferate in vitro, which creates the conditions suitable to
obtain large numbers of spermatogonial stem cells before
inducing them to differentiate during the process of gamete
production.
Recently, a novel three-dimensional testicular cell culture
approach was described. The soft agar culture system
(SACS), which was originally described for the culture of
hematopoietic cells in vitro, has created the conditions
necessary to enable the full development of murine male
germ cells in vitro (45-47). This system provides options for
manipulation, e.g., the testing of the effects of hormones,
drugs, toxins or other compounds on germ cell develop-
ment. We were able to demonstrate the progression of
spermatogonia into meiosis and the cells’ further matura-
tion into morphologically normal spermatozoa. However,
the efficiency of sperm production with SACS is very low.
The success of such strategies may depend on the
reconstruction of small functional units of testicular cells
inside the matrix, which occasionally fully resembles the
microenvironment in the seminiferous tubules and thus
results in small islands of complete spermatogenesis.
To recapitulate the situation in the testis, researchers must
sequentially and gradually provide the right substances/
conditions at the proper time, thereby emulating the in vivo
processes that occur in an orderly fashion in different
functional compartments (e.g., basal, meiotic, and adlum-
inal) of the seminiferous epithelium during normal in vivo
spermatogenesis. Apparently, the most challenging step of
differentiation to achieve in an in vitro spermatogenic
system is proceeding beyond meiosis (41). Hence, progress
must be experimentally monitored by meiotic/postmeiotic-
specific markers, by immunohistochemistry and/or by PCR.
Some examples are summarized in Table 1. The need to
distinguish somatic cells renders the use of markers for this
cell group useful (Table 2).
These findings have greatly inspired further research
involving humans in the hope of reversing cases of
incomplete spermatogenesis. This type of approach would
require biopsy procedures, which usually yield small
testicular samples with limited numbers of germ cells. If
the availability of testicular tissue is not an obstacle, then
fertility patients with immature germ cell arrest could
expect to overcome infertility by using this procedure.
Moreover, cell culture systems for in vitro spermatogenesis
would provide advantages not only to germ cell arrest
patients but also to type II SCO syndrome cases or cases
with other reproductive pathologies involving faulty sper-
matogonial stem cell niches.
Current technology allows, at least on the theoretical
level, SCO syndrome patients, who have no germ cells, to
achieve the goal of producing offspring that retain their own
genetic material. To this end, biotechnology must first
provide gametes to help these men overcome their fertility
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problems. Pluripotent stem cells could be a reliable and
plentiful source of immature germ cells to provide a
baseline for a differentiation process that eventually will
yield spermatozoa in vitro. Pluripotency is the property of a
cell to differentiate into somatic cells of ectodermal,
endodermal and mesodermal lineages, which constitute
the vast majority of the cells in the body (94). It has been
demonstrated that some pluripotent stem cells can also
generate germ cells. Pluripotent stem cells can be basically
obtained from two sources: a) the epiblast region in
blastodermic embryos, and b) adult somatic cells. The latter
source provides an opportunity for success in the great
challenge of obtaining pluripotent stem cells from adult
patients, despite the conventional wisdom in cell biology
that cells in tissues tend to progress into lineage restrictions
during development, gradually reaching terminal differen-
tiation. The idea of somatic pluripotentiation, or reprogram-
ming, has been discussed for quite some time and found
original success in mouse models (95). Efforts continued
shortly thereafter using human cells (96,97). Only recently,
independent research groups (98,99) went a step further to
achieve the major breakthrough of defining four basic
pluripotency-inducing factors, i.e., Oct4 (pouf1), Sox2, c-
Myc, and Klf4, which are required to switch somatic cells
into a pluripotent state, thus opening a window for deeper
understanding of pluripotency networks, as well as the
possibility of generating germ cells, among other cell types,
from somatic cells induced to be pluripotent (iPS cells). The
availability of such personalized germ cells of somatic origin
would be a prerequisite for an in vitro sperm-generating
system for SCO patients.
The development of in vitro spermatogenesis has bene-
fited from various animal models, including models that use
farm animals. Some culture systems were developed in
domestic animal models in which germ cells progressed to
advanced steps of spermatogenesis. For instance, Izadyar et
al. observed elongated spermatids in a long-term culture of
bovine germ cells (70), whereas Dong et al. obtained
elongated spermatids from fetal calf gonocyte cultures
(100). In these species, the available procedures proved to
be rather inefficient because not many terminally differ-
entiated gametes could be derived. In parallel, murine
models involving ES (embryonic stem) cells resulted in
advances in the field. In principle, germ cell derivation from
ES cells does not seem to be practical for infertility patients,
as almost no man has access to his own embryonic cells.
However, because iPS cells appear to be similar to ES cells
(101), and in nature, technically derivable from somatic
cells, the resulting scenario becomes very promising to drive
them into the production of gametes in vitro. Efforts to
generate germ cells and gametes from ES cells and iPS cells
in murine models and humans are summarized on Figure 3.
Briefly, three research groups have made advances in the
derivation of germ cells from mouse ES cells. One of these
groups produced gamete-like cells, and using ICSI as a
functional assay, they managed to obtain embryos after
fertilization had reached the blastocyst stage (102). Two
laboratories were able to generate sperm in vitro (31,103),
but only one of them obtained offspring by injecting the
derived sperm into donor oocytes using ICSI (31). However,
in this case, the offspring production had low efficiency (7
out of 65 embryos), and the mice that were born died
Table 1 - Testicular germ cell markers.
Cell type Marker
Germ cell general VASA (48) h
Gonocytes ZBTB16 (49) m,h
Undifferentiated type A spermatogonia (single) ID4 (50) m; CSF1R (51) m
Undifferentiated type A spermatogonia (single and paired) EFR3 (52) m
Undifferentiated type A spermatogonia (single, paired and aligned) THY1 (53) m; UTF1 (54) m; PLZF (55) m; LIN28 (TEX17) (56) m; NGN3 (57) m;
NANOS3 (52) m; CD24 (53) m; GFRalpha1 (57) m; CDH1 (58) m; GPR125 (59) m;
SOHLH2 (60) m; RET (61) m; BCL6B (62) m; SOX3 (63) m; SALL4 (64) p
Spermatogonia (general) HSP60 (65) h; MAGEA-4 (66) h; UCHL1 (PGP9.5) (66) h; ITGA6
(alpha6 integrin) (66) h; ZBTB16 (66) h, (49) m,h; Kit (36) m
Pachytene spermatocytes testis specific histone (TH2B)(67) r; phosphoprotein P19 (68) r; SPTRX-3 (69) h
Spermatocytes (general) SCP-3 (70) b, (71) h; GRP78 (65) h; Kit (66) h; MLH1 (71) h
Round spermatids Transition proteins T1, T2 (72,73) h; protamine 2 (PRM-2) (74); CREM (75) h,m;
GRP78 (65) h; Kit (66) h
Elongated spermatids CRES (76) h
Spermatids (general) SPANX (a subset) (77) h; KLF4 (78) h; SPTRX-3 (69) h; SP-10 (79) h; TGFbeta3 (80) h
Sperm outer dense fibers (ODF-2) (70); acrosin (81) b; SPANX (77); HSP60 (65) h; GRP78
(65) h; CRES (76) h; DAZ2 (82) h
m, mouse; r, rat; d, dog; b, bovine; p, non-human primate; h, human.
Table 2 - Testicular somatic cell markers.
Cell type Marker
Sertoli immature AMH (anti-mullerian hormone) (83) p; WT1 (Wilms’ tumor gene)- transcription factor (83) r; aromatase (P450
enzymes) (83) r; NCAM (neural cell adhesion molecule) (83) r; cytokeratin 18 (83,84) h; M2A (83) h
Sertoli mature occludin (85) m,r,d; vimentin (86) r, (43,87) b; P27Kip 1 (cyclin-dependent kinase inhibitor) (83) m,r,h; WT1
(Wilms` tumor gene)- transcription factor (83) r; Dmrt1 (88) m; Gata 4 (88) m; Gata 1(83) m; AR (androgen
receptor) (83) r,p,h; transferrin (88) r; ITGA6 (alpha6 integrin) (66) h
Leydig cells ITGalpha6 (alpha6 integrin) (66) h; RLF (89) m; 3 beta-HSD (90) g, (91) r; TGF alpha (92) r
Peritubular myoid cells alpha-smooth muscle actin (93) r, (43,87) b
m, mouse; r, rat; g, guinea pig; d, dog; b, bovine; p, non-human primate; h, human.
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Figure 3 - Recent advances in the derivation of germ cells / gametes from ES cells and iPS cells in mouse models (A) and in humans (B).
ESC, embryonic stem cells; iPS, induced pluripotent stem cells; PGCs, primordial germ cells; SSC, spermatogonial stem cells; HL, haploid-
like cells; ICSI, intracytoplasmatic sperm injection. In (A) arrows point into the cell types generated by each specific research group. Grey
letter X and arrow in (B) indicate advances not yet accomplished.
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prematurely (five months after birth), which suggests
developmental aberrations. Progress in germ cell derivation
frommouse iPS cells was initially more limited because none
of the groups involved could obtain offspring, although
PGCs were obtained in one case (104) and gamete-like cells
were also recently obtained (105). Recent advances have also
been made in humans. PGCs were derived from human ES
cells by several groups (30,106,107). Recently, Aflatoonian et
al. not only generated PGCs but also derived human sperm-
like cells (haploid-like cells) for the first time (108). In another
recent study, haploid-like cells were produced from human
iPS cells (33). Nevertheless, up to now, no human embryos
have been generated using these techniques, and the
scientific community continues to work together with
clinicians to develop rigorous, ethical and secure tests and
protocols for these innovative techniques.
The principles underlying these methods are simple
enough to allow further progress from experimental to
applied status. In summary, pluripotent ES cells are first
given a differentiation environment in vitro to produce
multiple cell lineages, and then, in a second phase, cells are
selected for specific antigen expression or reporter germ cell
genes. Also important is the addition of differentiating
factors. The current stage of methods for the derivation of
human haploid-like cells in vitro allows the generation of
gametes with the correct epigenetic status (32,109,110).
Taken together, all of the findings presented are genuine
biotechnological advances with potential applications in
cases of men who present with aspermatogenesis, but
regardless of the tremendous potential of these techniques
for the derivation of germ cells to produce gametes in vitro
using culture techniques, much research remains to be
conducted in this area.
& GERM STEM CELL TRANSPLANTATION AND
XENOLOGOUS SYSTEMS
In cases in which the testes of infertile men contain
spermatogonia, the stem cell fraction among these premeiotic
germ cells could be targeted for fertility preservation. The
presence of male germline stem cells indicates high regen-
erative potential, as these cells can efficiently recolonize the
seminiferous tubules, even when the starting population of
spermatogonial stem cells is small. When the technique was
first applied by Brinster and Zimmermann in 1994 (111), a
crude, single-cell suspension containing spermatogonia was
infused into the testis. The stem cells migrated into testicular
stem cell niches spontaneously, whereas somatic and more
differentiated germ cells were flushed out. Recolonization
was initiated from individual spermatogonia, which slowly
but steadily divided and migrated to repopulate all of the
seminiferous tubules (111,112).
The technique of germ cell transplantation could, in
principle, be applied across species. Microinjection of germ
cell suspensions from rats into the seminiferous tubules of
mice led to the initiation of spermatogenesis from donor
spermatogonial stem cells. Spermatogonia from less closely
related species have the ability to repopulate the testis but
will not differentiate, which currently renders the produc-
tion of primate sperm in mouse testes impossible.
Subsequent studies in rodents showed that spermatogonia
can be cryopreserved and expanded by in vitro culture prior
to germ cell transfer. The clinical potential of this technique
was shown in non-human primates and in experimental
studies using human testes. Ultrasound-guided infusion of
germ cell suspensions via the intratesticular rete testis
appears to offer a simple and relatively non-invasive
procedure for the autologous infusion of germ cells back
into the patient (113). Our preclinical studies have demon-
strated the feasibility of transplanting germ cell suspensions
into the testes of non-human primates and men (113,114). A
first clinical trial was initiated at the Christie Hospital in
Manchester, UK, in 1999. The fertility outcomes of the
patients in this study have not been yet published (115,116).
In conclusion, important issues in achieving re-fertilization
through germ cell transplantation include the retrieval of
sufficient testicular tissue or in vitro expansion strategies for
spermatogonia, prevention of ischemia in the dissected
tissues and cells, cryopreservation and thawing of cell
suspensions and sorting of tumor cells or enrichment of
spermatogonial stem cells. The only issue solved is the
ultrasound-guided non-invasive transfer of germ cell
suspensions into the rete testis. These critical steps must
be optimized by future research before this technique can
offer a promising and safe option for the protection of male
fertility in men with spermatogonial arrest.
Testicular grafting is an extreme form of organ culture in
which the tissue is transplanted into a host. The environ-
ment is well controlled, and also the blood supply to the
grafted tissue is restored. Immature testicular tissue has a
high regenerative capacity and can survive and develop as
an auto- or xenograft. In the absence of alternative strategies
to generate sperm in vitro, grafting provides an approach to
ex-vivo generation of mature sperm. In mice, sperm
generated in grafts were capable of generating healthy
offspring. We and others have recently shown that
xenografting of neonatal and prepubertal testicular tissue
from a variety of species permitted the generation of sperm,
whereas xenografting of more developed tissue resulted in
the degeneration of testicular tissue. We have also shown
that immature primate testes can be maintained on ice for
24 hours prior to xenografting and can also be cryopre-
served. Grafting will create exciting, clinically applicable
strategies for fertility preservation in immature patients.
However, fertility problems are usually diagnosed in
adulthood, when grafting appears to be a less useful tool
for generating sperm. We therefore consider the application
of grafting techniques to be more valuable for fertility
preservation in children undergoing oncological treatment.
An alternative to achieve germ cell development is the
use of xenologous systems, which recapitulate the organo-
genesis of a functional testis [for review: Gassei and Schlatt,
2007, (117)]. The male pathway involves regulated cell
differentiation of somatic cells within the gonadal primor-
dium, including the migration of mesonephric cells and
primordial germ cells. Finally, testis cords form and begin to
elongate. Tissue engineering approaches that mimic male
embryonic gonadogenesis could offer novel ways to study
early testicular differentiation (29) and may, when even-
tually combined with xenografting approaches, also provide
scenarios for the differentiation of male germ cells.
& HAPLOIDIZATION
In previous sections, several prospective technologies
were proposed to overcome the lack of gametes in men with
aspermatogenesis. These technologies are based on differ-
entiating preexisting or pluripotential stem cell-derived
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germ cells in vitro (spermatogenesis in vitro) or on in vivo
systems (transplantation and xenografting) to produce
sperm.
Haploidization is an alternative approach to manufacture
gametes based on biological cloning technology. In cloning,
an entire genome is obtained from a single individual when
he donates a somatic cell nucleus, which is transferred into an
enucleated, developmentally young cell (MII oocyte, zygote,
embryo) (118). In contrast, haploidization is a modified
cloning technique in which there is a genetic haploid
contribution from both parents, which is one reason why
this technique has also been called semi-cloning (119,120).
Although promising, this technology has not been
successful for generating live normal offspring in murine
experimental models, and therefore it remains largely
experimental, with no immediate prospects for clinical
application. For instance, in preliminary experiments, only
17 to 22% of mouse oocytes ‘‘fertilized’’ with somatic cells
formed blastocysts, and no offspring were derived from
them (121).
& EXPERT COMMENTS
This review article provides an overview of several
biotechnological approaches that have the potential to offer
solutions for a range of reproductive pathologies that cause
sterility in a significant number of azoospermic men, while
at the same time providing new tools to contribute to our
current knowledge of male reproductive physiology.
Although they are thus far experimental, the proposed
emerging technologies could work in combination with
other already well-established reproductive technologies
and take advantage of the requirement for just one healthy
spermatozoon to ensure successful fertilization and, hope-
fully, normal offspring from these individuals.
Thus far, only haploid-like cells, with an apparently
correct epigenetic status, have been generated by several
research groups. In the near future, we can expect the
generation of sperm as the most natural, terminally
differentiated cells to be used in assisted reproduction for
men afflicted with aspermatogenesis.
Regardless of the pervading optimism, remaining chal-
lenges include the verification of aspects such as normal
cytogenetics, epigenetic stability, the tumorogenic potential
of derived germ cells and even ethical aspects, which should
guarantee the correct implementation of these new repro-
ductive technologies. Additionally, the genetic basis for
many conditions of aspermatogenesis will necessitate cau-
tion, as well as a consideration of the need to develop gene
therapies that are specific for these reproductive problems to
prevent their transmission to future generations.
& KEY ISSUES
NAt least 25% of azoospermic men are sterile because
their testes either hold only immature or no germ cells at all,
a condition that can be collectively termed as aspermato-
genesis.
N Possible solutions to aspermatogenesis require biotech-
nological approaches to retain biological fatherhood.
NAzoospermic men with germ cell arrests at early stages
of spermatogenesis would benefit from sperm derivation in
vitro or ex vivo.
NAzoospermic men with type II SCO would have the
alternatives of germ cell derivation from a) somatic cells via
induced pluripotency or b) haploidization.
N The most challenging differentiation step in an in vitro
spermatogenic system is completion of meiosis which has
been achieved in several animal models by ex vivo
approaches or 3D culture systems.
N In the absence of alternative strategies, testicular
grafting (auto- or xenograft) should be considered to ex-
vivo generate mature sperm and would be more valuable
for fertility preservation in children undergoing oncological
treatment.
NHaploidization is a modified cloning technique, in
which each parent genetically contributes with a haploid
complement, but unfortunately this technique offers no
immediate perspective for clinical application.
NAlthough extensive research has been and continues to
be performed, biotechnologies described on this review
article still remain largely experimental.
& ACKNOWLEDGMENTS
This study was supported by CNPq and FAPEMIG.
& AUTHOR CONTRIBUTIONS
All of the authors who are listed participated sufficiently in the present
review article and therefore take public responsibility for its content.
& REFERENCES
1. Evers JL. Female subfertility. Lancet. 2002;360(9327):151-9, http://dx.
doi.org/10.1016/S0140-6736(02)09417-5.
2. Tuttelmann F, Simoni M, Kliesch S, Ledig S, Dworniczak B, Wieacker P,
et al. Copy number variants in patients with severe oligozoospermia
and Sertoli-cell-only syndrome. PloS one. 2011;6(4):e19426, http://dx.
doi.org/10.1371/journal.pone.0019426.
3. Tuttelmann F, Werny F, Cooper TG, Kliesch S, Simoni M, Nieschlag E.
Clinical experience with azoospermia: aetiology and chances for
spermatozoa detection upon biopsy. Int J Androl. 2011;34(4):291-8.
4. Hamada A, Esteves SC, Agarwal A. Unexplained male infertility:
potential causes and management. Hum Androl. 2011;1:2-16, http://dx.
doi.org/10.1097/01.XHA.0000397686.82729.09.
5. McLachlan RI, Rajpert-De Meyts E, Hoei-Hansen CE, de Kretser DM,
Skakkebaek NE. Histological evaluation of the human testis -
approaches to optimizing the clinical value of the assessment: Mini
Review. Hum Reprod. 2007;22(1):2-16.
6. Anniballo R, Brehm R, Steger K. Recognising the Sertoli-cell-only (SCO)
syndrome: a case study. Andrologia. 2011;43(1):78-83, http://dx.doi.
org/10.1111/j.1439-0272.2009.01030.x.
7. Li HG, Wu CL, Gu XL, Xiong CL. A novel application of cell-free
seminal mRNA: non-invasive identification of the presence of germ
cells or complete obstruction in men with azoospermia. Hum Reprod.
2012;27(4):991-7, http://dx.doi.org/10.1093/humrep/der481.
8. Kimura Y, Yanagimachi R. Development of Normal Mice from Oocytes
Injected with Secondary Spermatocyte Nuclei. Biol Reprod. 1995;
53(4):855-62, http://dx.doi.org/10.1095/biolreprod53.4.855.
9. Ogura A, Suzuki O, Tanemura K, Mochida K, Kobayashi Y, Matsuda J.
Development of normal mice from metaphase I oocytes fertilized with
primary spermatocytes. P Natl Acad Sci USA. 1998;95(10):5611-5,
http://dx.doi.org/10.1073/pnas.95.10.5611.
10. Sofikitis N, Mantzavinos T, Loutradis D, Yamamoto Y, Tarlatzis V,
Miyagawa I. Ooplasmic injections of secondary spermatocytes for non-
obstructive azoospermia. Lancet. 1998;351(9110):1177-8, http://dx.doi.
org/10.1016/S0140-6736(05)79121-2.
11. Aksglaede L, Wikstrom AM, Rajpert-De Meyts E, Dunkel L, Skakkebaek
NE, Juul A. Natural history of seminiferous tubule degeneration in
Klinefelter syndrome. Hum Reprod Update. 2006;12(1):39-48.
12. Yamamoto M, Yokoi K, Katsuno S, Hibi H, Miyake K. A case of sex
reversal syndrome with sex-determining region (XX male). Nagoya
journal of medical science. 1995;58(3-4):111-5.
13. Shapiro CE. Unbalanced chromosomal translocation associated with
Sertoli-cell-only histology. J Urol. 1991;145(3):563-4.
Artificial sperm generation
Aponte PM et al.
CLINICS 2013;68(S1):157-167
164
14. Cacheiro NL, Russell LB, Swartout MS. Translocations, the predomi-
nant cause of total sterility in sons of mice treated with mutagens.
Genetics. 1974;76(1):73-91.
15. Kamp C, Huellen K, Fernandes S, Sousa M, Schlegel PN, Mielnik A,
et al. High deletion frequency of the complete AZFa sequence in men
with Sertoli-cell-only syndrome. Mol Hum Reprod. 2001;7(10):987-94,
http://dx.doi.org/10.1093/molehr/7.10.987.
16. Yang Y, Ma MY, Xiao CY, Li L, Li SW, Zhang SZ. Massive deletion in
AZFb/b plus c and azoospermia with Sertoli cell only and/or
maturation arrest. Int J Androl. 2008;31(6):573-8.
17. Steinberger A, Steinberger E. In vitro culture of rat testicular cells. Exp
Cell Res. 1966;44(2):443-52, http://dx.doi.org/10.1016/0014-4827(66)
90451-4.
18. Goldschmidt R. Some experiments on spermatogenesis in vitro. P Natl
Acad Sci USA. 1915;1:220-2, http://dx.doi.org/10.1073/pnas.1.4.220.
19. Miura T, Yamauchi K, Takahashi H, Nagahama Y. Human Chorionic-
Gonadotropin Induces All Stages of Spermatogenesis Invitro in the
Male Japanese Eel (Anguilla-Japonica). Dev Biol. 1991;146(1):258-62,
http://dx.doi.org/10.1016/0012-1606(91)90468-I.
20. Miura T, Yamauchi K, Takahashi H, Nagahama Y. Hormonal induction
of all stages of spermatogenesis in vitro in the male Japanese eel
(Anguilla japonica). Proc Natl Acad Sci U S A. 1991;88(13):5774-8,
http://dx.doi.org/10.1073/pnas.88.13.5774.
21. Hong Y, Liu T, Zhao H, Xu H, Wang W, Liu R, et al. Establishment of a
normal medakafish spermatogonial cell line capable of sperm produc-
tion in vitro. Proc Natl Acad Sci U S A. 2004;101(21):8011-6, http://dx.
doi.org/10.1073/pnas.0308668101.
22. Sato T, Katagiri K, Gohbara A, Inoue K, Ogonuki N, Ogura A, et al. In
vitro production of functional sperm in cultured neonatal mouse testes.
Nature. 2011;471(7339):504-7, http://dx.doi.org/10.1038/nature09850.
23. Tesarik J, Greco E, Rienzi L, Ubaldi F, Guido M, Cohen-Bacrie P, et al.
Differentiation of spermatogenic cells during in-vitro culture of
testicular biopsy samples from patients with obstructive azoospermia:
effect of recombinant follicle stimulating hormone. Hum Reprod.
1998;13(10):2772-81, http://dx.doi.org/10.1093/humrep/13.10.2772.
24. Tanaka A, Nagayoshi M, Awata S, Mawatari Y, Tanaka I, Kusunoki H.
Completion of meiosis in human primary spermatocytes through in
vitro coculture with Vero cells. Fertil Steril. 2003;79:795-801, http://dx.
doi.org/10.1016/S0015-0282(02)04833-1.
25. Parvinen M, Wright WW, Phillips DM, Mather JP, Musto NA, Bardin
CW. Spermatogenesis Invitro - Completion of Meiosis and Early
Spermiogenesis. Endocrinology. 1983;112(3):1150-2, http://dx.doi.org/
10.1210/endo-112-3-1150.
26. Tres LL, Kierszenbaum AL. Viability of Rat Spermatogenic Cells-Invitro
Is Facilitated by Their Co-Culture with Sertoli Cells in Serum-Free
Hormone-Supplemented Medium. P Natl Acad Sci-Biol. 1983;80(11):
3377-81, http://dx.doi.org/10.1073/pnas.80.11.3377.
27. Oatley JM, de Avila DM, Reeves JJ, McLean DJ. Testis tissue explant
culture supports survival and proliferation of bovine spermatogonial
stem cells. Biol Reprod. 2004;70(3):625-31.
28. Lee JH, Kim HJ, Kim H, Lee SJ, Gye MC. In vitro spermatogenesis by three-
dimensional culture of rat testicular cells in collagen gel matrix. Biomaterials.
2006;27(14):2845-53, http://dx.doi.org/10.1016/j.biomaterials.2005.12.028.
29. Gassei K, Ehmcke J, Schlatt S. Initiation of testicular tubulogenesis is
controlled by neurotrophic tyrosine receptor kinases in a three-
dimensional Sertoli cell aggregation assay. Reproduction. 2008;
136(4):459-69, http://dx.doi.org/10.1530/REP-08-0241.
30. Tilgner K, Atkinson SP, Golebiewska A, Stojkovic M, Lako M,
Armstrong L. Isolation of Primordial Germ Cells from Differentiating
Human Embryonic Stem Cells. Stem Cells. 2008;26(12):3075-85, http://
dx.doi.org/10.1634/stemcells.2008-0289.
31. Nayernia K, Nolte J, Michelmann HW, Lee JH, Rathsack K,
Drusenheimer N, et al. In vitro-differentiated embryonic stem cells
give rise to male gametes that can generate offspring mice. Dev Cell.
2006;11(1):125-32, http://dx.doi.org/10.1016/j.devcel.2006.05.010.
32. Medrano JV, Ramathal C, Nguyen HN, Simon C, Pera RAR. Divergent
RNA-Binding Proteins, DAZL and VASA, Induce Meiotic Progression
in Human Germ Cells Derived In Vitro. Stem Cells. 2012;30(3):441-51,
http://dx.doi.org/10.1002/stem.1012.
33. Eguizabal C, Montserrat N, Vassena R, Barragan M, Garreta E, Garcia-
Quevedo L, et al. Complete Meiosis from Human Induced Pluripotent
Stem Cells. Stem Cells. 2011;29(8):1186-95, http://dx.doi.org/10.1002/
stem.672.
34. Hogarth CA, Griswold MD. The key role of vitamin A in spermatogen-
esis. J Clin Invest. 2010;120(4):956-62, http://dx.doi.org/10.1172/
JCI41303.
35. van Pelt AM, Morena AR, van Dissel-Emiliani FM, Boitani C, Gaemers
IC, de Rooij DG, et al. Isolation of the synchronized A spermatogonia
from adult vitamin A-deficient rat testes. Biol Reprod. 1996;55(2):439-44,
http://dx.doi.org/10.1095/biolreprod55.2.439.
36. Schrans-Stassen BH, van de Kant HJ, de Rooij DG, van Pelt AM.
Differential expression of c-kit in mouse undifferentiated and differ-
entiating type A spermatogonia. Endocrinology. 1999;140(12):5894-900,
http://dx.doi.org/10.1210/en.140.12.5894.
37. Feng LX, Chen Y, Dettin L, Pera RA, Herr JC, Goldberg E, et al. Generation
and in vitro differentiation of a spermatogonial cell line. Science.
2002;297(5580):392-5, http://dx.doi.org/10.1126/science.1073162.
38. Tajima Y, Watanabe D, Koshimizu U, Matsuzawa T, Nishimune Y.
Insulin-like growth factor-I and transforming growth factor-alpha
stimulate differentiation of type A spermatogonia in organ culture of
adult mouse cryptorchid testes. Int J Androl. 1995;18(1):8-12.
39. Walker WH, Cheng J. FSH and testosterone signaling in Sertoli cells.
Reproduction. 2005;130(1):15-28, http://dx.doi.org/10.1530/rep.1.00358.
40. Tesarik J, Mendoza C, Greco E. The effect of FSH on male germ cell
survival and differentiation in vitro is mimicked by pentoxifylline but
not insulin. Mol Hum Reprod. 2000;6(10):877-81, http://dx.doi.org/10.
1093/molehr/6.10.877.
41. Godet M, Sabido O, Gilleron J, Durand P. Meiotic progression of rat
spermatocytes requires mitogen-activated protein kinases of Sertoli
cells and close contacts between the germ cells and the Sertoli cells. Dev
Biol. 2008;315(1):173-88, http://dx.doi.org/10.1016/j.ydbio.2007.12.019.
42. Aponte PM, Soda T, van de Kant HJ, de Rooij DG. Basic features of
bovine spermatogonial culture and effects of glial cell line-derived
neurotrophic factor. Theriogenology. 2006;65(9):1828-47, http://dx.doi.
org/10.1016/j.theriogenology.2005.10.020.
43. Aponte PM, Soda T, Teerds KJ, Mizrak SC, van de Kant HJ, de Rooij
DG. Propagation of bovine spermatogonial stem cells in vitro.
Reproduction. 2008;136(5):543-57, http://dx.doi.org/10.1530/REP-07-
0419.
44. Kierszenbaum AL. Mammalian spermatogenesis in vivo and in vitro: a
partnership of spermatogenic and somatic cell lineages. Endocr Rev.
1994;15(1):116-34.
45. Stukenborg JB, Schlatt S, Simoni M, Yeung CH, Elhija MA, Luetjens CM,
et al. New horizons for in vitro spermatogenesis? An update on novel
three-dimensional culture systems as tools for meiotic and post-meiotic
differentiation of testicular germ cells. Mol Hum Reprod. 2009;15(9):
521-9, http://dx.doi.org/10.1093/molehr/gap052.
46. Stukenborg JB, Wistuba J, Luetjens CM, Elhija MA, Huleihel M, Lunenfeld
E, et al. Coculture of spermatogonia with somatic cells in a novel three-
dimensional soft-agar-culture-system. J Androl. 2008;29(3):312-29.
47. Abu Elhija M, Lunenfeld E, Schlatt S, Huleihel M. Differentiation of
murine male germ cells to spermatozoa in a soft agar culture system.
Asian J Androl. 2012;14(2):285-93.
48. Castrillon DH, Quade BJ, Wang TY, Quigley C, Crum CP. The human
VASA gene is specifically expressed in the germ cell lineage. Proc Natl
Acad Sci U S A. 2000;97(17):9585-90, http://dx.doi.org/10.1073/pnas.
160274797.
49. Wu X, Schmidt JA, Avarbock MR, Tobias JW, Carlson CA, Kolon TF,
et al. Prepubertal human spermatogonia and mouse gonocytes share
conserved gene expression of germline stem cell regulatory molecules.
Proc Natl Acad Sci U S A. 2009;106(51):21672-7, http://dx.doi.org/10.
1073/pnas.0912432106.
50. OatleyMJ, Kaucher AV, Racicot KE, Oatley JM. Inhibitor of DNAbinding
4 is expressed selectively by single spermatogonia in the male germline
and regulates the self-renewal of spermatogonial stem cells in mice.
Biol Reprod. 2011;85(2):347-56, http://dx.doi.org/10.1095/biolreprod.
111.091330.
51. Oatley JM, Oatley MJ, Avarbock MR, Tobias JW, Brinster RL. Colony
stimulating factor 1 is an extrinsic stimulator of mouse spermatogonial
stem cell self-renewal. Development. 2009;136(7):1191-9, http://dx.doi.
org/10.1242/dev.032243.
52. Tsuda M, Sasaoka Y, Kiso M, Abe K, Haraguchi S, Kobayashi S, et al.
Conserved role of nanos proteins in germ cell development. Science.
2003;301(5637):1239-41, http://dx.doi.org/10.1126/science.1085222.
53. Kubota H, Avarbock MR, Brinster RL. Spermatogonial stem cells share
some, but not all, phenotypic and functional characteristics with other
stem cells. Proc Natl Acad Sci U S A. 2003;100(11):6487-92, http://dx.
doi.org/10.1073/pnas.0631767100.
54. van Bragt MP, Roepers-Gajadien HL, Korver CM, Bogerd J, Okuda A,
Eggen BJ, et al. Expression of the pluripotency marker UTF1 is
restricted to a subpopulation of early A spermatogonia in rat testis.
Reproduction. 2008;136(1):33-40, http://dx.doi.org/10.1530/REP-07-
0536.
55. Grisanti L, Falciatori I, Grasso M, Dovere L, Fera S, Muciaccia B, et al.
Identification of spermatogonial stem cell subsets by morphological
analysis and prospective isolation. Stem Cells. 2009;27(12):3043-52.
56. Zheng K, Wu X, Kaestner KH, Wang PJ. The pluripotency factor LIN28
marks undifferentiated spermatogonia in mouse. BMC Dev Biol.
2009;9:38, http://dx.doi.org/10.1186/1471-213X-9-38.
57. Yoshida S. Stem cells in mammalian spermatogenesis. Dev Growth
Differ. 2010;52(3):311-7, http://dx.doi.org/10.1111/j.1440-169X.2010.
01174.x.
58. Tokuda M, Kadokawa Y, Kurahashi H, Marunouchi T. CDH1 is a
specific marker for undifferentiated spermatogonia in mouse testes.
Biol Reprod. 2007;76(1):130-41, http://dx.doi.org/10.1095/biolreprod.
106.053181.
CLINICS 2013;68(S1):157-167 Artificial sperm generation
Aponte PM et al.
165
59. Seandel M, Falciatori I, Shmelkov SV, Kim J, James D, Rafii S. Niche
players: spermatogonial progenitors marked by GPR125. Cell Cycle.
2008;7(2):135-40, http://dx.doi.org/10.4161/cc.7.2.5248.
60. Ballow DJ, Xin Y, Choi Y, Pangas SA, Rajkovic A. Sohlh2 is a germ cell-
specific bHLH transcription factor. Gene Expr Patterns. 2006;6(8):1014-
8, http://dx.doi.org/10.1016/j.modgep.2006.04.007.
61. Ebata KT, Zhang X, Nagano MC. Expression patterns of cell-surface
molecules on male germ line stem cells during postnatal mouse
development. Mol Reprod Dev. 2005;72(2):171-81, http://dx.doi.org/
10.1002/mrd.20324.
62. Oatley JM, Avarbock MR, Telaranta AI, Fearon DT, Brinster RL.
Identifying genes important for spermatogonial stem cell self-renewal
and survival. Proc Natl Acad Sci U S A. 2006;103(25):9524-9, http://dx.
doi.org/10.1073/pnas.0603332103.
63. Raverot G, Weiss J, Park SY, Hurley L, Jameson JL. Sox3 expression in
undifferentiated spermatogonia is required for the progression of
spermatogenesis. . Dev Biol. 2005;283(1):215-25, http://dx.doi.org/10.
1016/j.ydbio.2005.04.013.
64. Eildermann K, Aeckerle N, Debowski K, Godmann M, Christiansen H,
Heistermann M, et al. Developmental Expression of the Pluripotency
Factor Sal-Like Protein 4 in the Monkey, Human and Mouse Testis:
Restriction to Premeiotic Germ Cells. Cells Tissues Organs.
2012;196(3):206-20, http://dx.doi.org/10.1159/000335031.
65. Lachance C, Fortier M, Thimon V, Sullivan R, Bailey JL, Leclerc P.
Localization of Hsp60 and Grp78 in the human testis, epididymis and
mature spermatozoa. Int J Androl. 2010;33(1):33-44.
66. He ZP, Kokkinaki M, Jiang JJ, Dobrinski I, Dym M. Isolation,
Characterization, and Culture of Human Spermatogonia. Biol Reprod.
2010;82(2):363-72, http://dx.doi.org/10.1095/biolreprod.109.078550.
67. Unni E, Mayerhofer A, Zhang Y, Bhatnagar YM, Russell LD, Meistrich
ML. Increased Accessibility of the N-Terminus of Testis-Specific
Histone Th2b to Antibodies in Elongating Spermatids. Mol Reprod
Dev. 1995;42(2):210-9, http://dx.doi.org/10.1002/mrd.1080420210.
68. Hue D, Staub C, Perrard-Sapori MH, Weiss M, Nicolle JC, Vigier M,
et al. Meiotic differentiation of germinal cells in three-week cultures of
whole cell population from rat seminiferous tubules. Biol Reprod.
1998;59(2):379-87, http://dx.doi.org/10.1095/biolreprod59.2.379.
69. Jimenez A, Zu W, Rawe VY, Pelto-Huikko M, Flickinger CJ, Sutovsky P,
et al. Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi
apparatus-associated thioredoxin, is a specific marker of aberrant
spermatogenesis. J Biol Chem. 2004;279(33):34971-82, http://dx.doi.
org/10.1074/jbc.M404192200.
70. Izadyar F, den Ouden K, Creemers LB, Posthuma G, Parvinen M, de
Rooij DG. Proliferation and differentiation of bovine type A sperma-
togonia during long-term culture. Biol Reprod. 2003;68(1):272-81.
71. Ko E, Martin RH. Immunofluorescence analysis of human spermato-
cytes. Methods Mol Biol. 2009;558:401-18, http://dx.doi.org/10.1007/
978-1-60761-103-5_23.
72. Alfonso PJ, Kistler WS. Immunohistochemical localization of spermatid
nuclear transition protein 2 in the testes of rats and mice. Biol Reprod.
1993;48(3):522-9, http://dx.doi.org/10.1095/biolreprod48.3.522.
73. Steger K, Klonisch T, Gavenis K, Drabent B, Doenecke D, Bergmann M.
Expression of mRNA and protein of nucleoproteins during human
spermiogenesis. Mol Hum Reprod. 1998;4(10):939-45, http://dx.doi.
org/10.1093/molehr/4.10.939.
74. Steger K, Fink L, Klonisch T, Bohle RM, Bergmann M. Protamine-1 and-
2 mRNA in round spermatids is associated with RNA-binding proteins.
Histochem Cell Biol. 2002;117(3):227-34, http://dx.doi.org/10.1007/
s00418-002-0385-3.
75. Steger K, Behr R, Kleiner I, Weinbauer GF, Bergmann M. Expression of
activator of CREM in the testis (ACT) during normal and impaired
spermatogenesis: correlation with CREM expression. Molecular human
reproduction. 2004;10(2):129-35, http://dx.doi.org/10.1093/molehr/
gah012.
76. Wassler M, Syntin P, Sutton-Walsh HG, Hsia N, Hardy DM, Cornwall
GA. Identification and characterization of cystatin-related epididymal
spermatogenic protein in human spermatozoa: Localization in the
equatorial segment. Biol Reprod. 2002;67(3):795-803, http://dx.doi.org/
10.1095/biolreprod.102.003970.
77. Salemi M, Calogero AE, Di Benedetto D, Cosentino A, Barone N,
Rappazzo G, et al. Expression of SPANX proteins in human-ejaculated
spermatozoa and sperm precursors. Int J Androl. 2004;27(3):134-9.
78. Behr R, Deller C, Godmann M, Muller T, Bergmann M, Ivell R, et al.
Kruppel-like factor 4 expression in normal and pathological human
testes. Mol Hum Reprod. 2007;13(11):815-20, http://dx.doi.org/10.
1093/molehr/gam064.
79. Kurth BE, Klotz K, Flickinger CJ, Herr JC. Localization of sperm antigen
SP-10 during the six stages of the cycle of the seminiferous epithelium
in man. Biol Reprod. 1991;44(5):814-21, http://dx.doi.org/10.1095/
biolreprod44.5.814.
80. Zhang YQ, He XZ, Zhang JS, Wang RA, Zhou J, Xu RJ. Stage-specific
localization of transforming growth factor beta1 and beta3 and their
receptors during spermatogenesis in men. Asian J Androl. 2004;6(2):105-
9.
81. De los Reyes M, Barros C. Immunolocalization of proacrosin/acrosin in
bovine sperm and sperm penetration through the zona pellucida. Anim
Reprod Sci. 2000;58(3-4):215-28, http://dx.doi.org/10.1016/S0378-
4320(99)00077-9.
82. Habermann B, Mi HF, Edelmann A, Bohring C, Backert IT, Kiesewetter
F, et al. DAZ (Deleted in AZoospermia) genes encode proteins located
in human late spermatids and in sperm tails. Hum Reprod.
1998;13(2):363-9, http://dx.doi.org/10.1093/humrep/13.2.363.
83. Sharpe RM, McKinnell C, Kivlin C, Fisher JS. Proliferation and
functional maturation of Sertoli cells, and their relevance to disorders
of testis function in adulthood. Reproduction. 2003;125(6):769-84,
http://dx.doi.org/10.1530/rep.0.1250769.
84. Kruse R, Eigelshoven S, Kaiser A, Ruzicka T, Neumann NJ. Cytokeratin
18 expression in immature Sertoli cells: Co-localization with interstitial
lymphocytic infiltrates. Folia Histochem Cyto. 2009;47(1):127-30,
http://dx.doi.org/10.2478/v10042-009-0009-z.
85. Morrow CMK, Mruk D, Cheng CY, Hess RA. Claudin and occludin
expression and function in the seminiferous epithelium. Philos T R Soc B.
2010;365(1546):1679-96.
86. Franke WW, Grund C, Schmid E. Intermediate-Sized Filaments Present
in Sertoli Cells Are of the Vimentin Type. Eur J Cell Biol. 1979;19(3):269-
75.
87. Devkota B, Sasaki M, Takahash KI, Matsuzaki S, Matsui M, Haneda S,
et al. Postnatal developmental changes in immunohistochemical
localization of alpha-smooth muscle actin (SMA) and vimentin in
bovine testes. J Reprod Develop. 2006;52(1):43-9, http://dx.doi.org/10.
1262/jrd.17062.
88. Buzzard JJ, Wreford NG, Morrison JR. Thyroid hormone, retinoic acid,
and testosterone suppress proliferation and induce markers of
differentiation in cultured rat Sertoli cells. Endocrinology.
2003;144(9):3722-31, http://dx.doi.org/10.1210/en.2003-0379.
89. Balvers M, Spiess AN, Domagalski R, Hunt N, Kilic E, Mukhopadhyay
AK, et al. Relaxin-like factor expression as a marker of differentiation in
the mouse testis and ovary. Endocrinology. 1998;139(6):2960-70, http://
dx.doi.org/10.1210/en.139.6.2960.
90. Dupont E, Luuthe V, Labrie F, Pelletier G. Light Microscopic
Immunocytochemical Localization of 3-Beta-Hydroxy-5-Ene-Steroid
Dehydrogenase Delta-5-Delta-4-Isomerase in the Gonads and
Adrenal-Glands of the Guinea-Pig. Endocrinology. 1990;126(6):2906-9,
http://dx.doi.org/10.1210/endo-126-6-2906.
91. Dupont E, Zhao HF, Rheaume E, Simard J, Luuthe V, Labrie F, et al.
Localization of 3-Beta-Hydroxysteroid Dehydrogenase Delta-5-Delta-4-
Isomerase in Rat Gonads and Adrenal-Glands by Immunocytochemistry
and Insitu Hybridization. Endocrinology. 1990;127(3):1394-403, http://
dx.doi.org/10.1210/endo-127-3-1394.
92. Teerds KJ, de Boer-Brouwer M, Dorrington JH, Balvers M, Ivell R.
Identification of markers for precursor and Leydig cell differentiation in
the adult rat testis following ethane dimethyl sulphonate administra-
tion. Biol Reprod. 1999;60(6):1437-45, http://dx.doi.org/10.1095/
biolreprod60.6.1437.
93. Tung PS, Fritz IB. Characterization of Rat Testicular Peritubular Myoid
Cells in Culture - Alpha-Smooth Muscle Isoactin Is a Specific
Differentiation Marker. Biol Reprod. 1990;42(2):351-65, http://dx.doi.
org/10.1095/biolreprod42.2.351.
94. Greenow K, Clarke AR. Controlling the Stem Cell Compartment and
Regeneration in Vivo: The Role of Pluripotency Pathways. Physiol Rev.
2012;92(1):75-99, http://dx.doi.org/10.1152/physrev.00040.2010.
95. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell.
2006;126(4):663-76, http://dx.doi.org/10.1016/j.cell.2006.07.024.
96. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K,
et al. Induction of pluripotent stem cells from adult human fibroblasts
by defined factors. Cell. 2007;131(5):861-72, http://dx.doi.org/10.1016/
j.cell.2007.11.019.
97. Yu JY, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL,
Tian S, et al. Induced pluripotent stem cell lines derived from human
somatic cells. Science. 2007;318(5858):1917-20, http://dx.doi.org/10.
1126/science.1151526.
98. Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts
by four transcription factors. Cell Prolif. 2008;41 Suppl 1:51-6.
99. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al.
Reprogramming of human somatic cells to pluripotency with defined
factors. Nature. 2008;451(7175):141-6, http://dx.doi.org/10.1038/
nature06534.
100. Dong WZ, Hua JL, Shen WZ, Dou ZY. In vitro production of haploid
sperm cells from male germ cells of foetal cattle. Anim Reprod Sci.
2010;118(2-4):103-9, http://dx.doi.org/10.1016/j.anireprosci.2009.06.018.
101. Yee J. Turning Somatic Cells into Pluripotent Stem Cells. Nature
Education. 2010;3(9):25.
102. Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ.
Derivation of embryonic germ cells and male gametes from embryonic
stem cells. Nature. 2004;427(6970):148-54, http://dx.doi.org/10.1038/
nature02247.
Artificial sperm generation
Aponte PM et al.
CLINICS 2013;68(S1):157-167
166
103. Toyooka Y, Tsunekawa N, Akasu R, Noce T. Embryonic stem cells can
form germ cells in vitro. P Natl Acad Sci USA. 2003;100(20):11457-62,
http://dx.doi.org/10.1073/pnas.1932826100.
104. Imamura M, Aoi T, Tokumasu A, Mise N, Abe K, Yamanaka S, et al.
Induction of Primordial Germ Cells From Mouse Induced Pluripotent
Stem Cells Derived From Adult Hepatocytes. Mol Reprod Dev.
2010;77(9):802-11, http://dx.doi.org/10.1002/mrd.21223.
105. Zhu Y, Hu HL, Li P, Yang S, Zhang W, Ding H, et al. Generation of male
germ cells from induced pluripotent stem cells (iPS cells): an in vitro
and in vivo study. Asian J Androl. 2012;14(4):574-9.
106. Tilgner K, Atkinson SP, Yung S, Golebiewska A, Stojkovic M, Moreno R,
et al. Expression of GFP Under the Control of the RNA Helicase VASA
Permits Fluorescence-Activated Cell Sorting Isolation of Human
Primordial Germ Cells. Stem Cells. 2010;28(1):84-92.
107. Bucay N, Yebra M, Cirulli V, Afrikanova I, Kaido T, Hayek A, et al. A
Novel Approach for the Derivation of Putative Primordial Germ Cells
and Sertoli Cells from Human Embryonic Stem Cells. Stem Cells.
2009;27(1):68-77, http://dx.doi.org/10.1634/stemcells.2007-1018.
108. Aflatoonian B, Ruban L, Jones M, Aflatoonian R, Fazeli A, Moore HD.
In vitro post-meiotic germ cell development from human embryonic
stem cells. Human Reproduction. 2009;24(12):3150-9, http://dx.doi.
org/10.1093/humrep/dep334.
109. Panula S, Medrano JV, Kee K, Bergstrom R, Ha NN, Byers B, et al.
Human germ cell differentiation from fetal- and adult-derived induced
pluripotent stem cells. Hum Mol Genet. 2011;20(4):752-62, http://dx.
doi.org/10.1093/hmg/ddq520.
110. Kee K, Angeles VT, Flores M, Nguyen HN, Pera RAR. Human DAZL,
DAZ and BOULE genes modulate primordial germ-cell and haploid
gamete formation. Nature. 2009;462(7270):222-U95, http://dx.doi.org/
10.1038/nature08562.
111. Brinster RL, Zimmermann JW. Spermatogenesis Following Male Germ-
Cell Transplantation. P Natl Acad Sci USA. 1994;91(24):11298-302,
http://dx.doi.org/10.1073/pnas.91.24.11298.
112. Brinster RL, Avarbock MR. Germline Transmission of Donor Haplotype
Following Spermatogonial Transplantation. P Natl Acad Sci USA.
1994;91(24):11303-7, http://dx.doi.org/10.1073/pnas.91.24.11303.
113. Schlatt S, Rosiepen G, Weinbauer GF, Rolf C, Brook PF, Nieschlag E.
Germ cell transfer into rat, bovine, monkey and human testes. Hum
Reprod. 1999;14(1):144-50, http://dx.doi.org/10.1093/humrep/14.1.
144.
114. Schlatt S, Foppiani L, Rolf C, Weinbauer GF, Nieschlag E. Germ cell
transplantation into X-irradiated monkey testes. Hum Reprod.
2002;17(1):55-62, http://dx.doi.org/10.1093/humrep/17.1.55.
115. Radford J, Shalet S, Lieberman B. Fertility after treatment for cancer.
Questions remain over ways of preserving ovarian and testicular tissue.
BMJ. 1999;319(7215):935-6, http://dx.doi.org/10.1136/bmj.319.7215.935.
116. Radford J. Restoration of fertility after treatment for cancer. Horm Res.
2003;59 Suppl 1:21-3, http://dx.doi.org/10.1159/000067840.
117. Gassei K, Schlatt S. Testicular morphogenesis: comparison of in vivo
and in vitro models to study male gonadal development. Ann N Y Acad
Sci. 2007;1120:152-67, http://dx.doi.org/10.1196/annals.1411.015.
118. Campbell KH, Fisher P, Chen WC, Choi I, Kelly RD, Lee JH, et al.
Somatic cell nuclear transfer: Past, present and future perspectives.
Theriogenology. 2007;68 Suppl 1:S214-31, http://dx.doi.org/10.1016/j.
theriogenology.2007.05.059.
119. Eichenlaub-Ritter U. Reproductive semi-cloning respecting biparen-
tal origin. Reconstitution of gametes for assisted reproduction. Hum
Reprod. 2003;18(3):473-5, http://dx.doi.org/10.1093/humrep/deg0
80.
120. Tesarik J. Reproductive semi-cloning respecting biparental embryo
origin - Embryos from syngamy between a gamete and a haploidized
somatic cell. Hum Reprod. 2002;17(8):1933-7, http://dx.doi.org/10.
1093/humrep/17.8.1933.
121. Lacham-Kaplan O, Daniels R, Trounson A. Fertilization of mouse
oocytes using somatic cells as male germ cells. Reprod Biomed Online
2001;3(3):205-211, http://dx.doi.org/10.1016/S1472-6483(10)62037-8.
CLINICS 2013;68(S1):157-167 Artificial sperm generation
Aponte PM et al.
167
